Table 3 Magnitude and characteristics of anemia among adult patients taking AZT based HAART treatment at University of Gondar Specialized Referral Hospital ART clinic from January 2016—February 2018
Variables | Category | Anemia status | Â | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
6Â month | 12Â month | 18Â month | 24Â month | 30Â month | Â | |||||||
Yes N (%) | No N (%) | Yes N (%) | No N (%) | Yes N (%) | No N (%) | Yes N (%) | No N (%) | Yes N (%) | No N (%) | Â | ||
Age of ART initiation | < 35 years | 52 (47) | 58 (53) | 36 (33) | 74 (67) | 44 (40) | 66 (60) | 44 (40) | 66 (60) | 43 (39) | 67 (61) |  |
35–45 years | 54 (41) | 79 (59) | 49(37) | 84 (63) | 51 (38) | 82 (62) | 57 (43) | 76 (57) | 54 (41) | 79 (59) |  | |
> 45 years | 35 (46) | 42 (54) | 29(38) | 48 (62) | 33 (43) | 44 (57) | 29 (38) | 48 (62) | 28 (36) | 49 (64) |  | |
Sex | Male | 65 (53) | 57 (47) | 40(33) | 82 (67) | 53 (43) | 69 (57) | 58 (48) | 64 (52) | 45 (37) | 77 (63) | Â |
Female | 76 (38) | 122 (62) | 74(37) | 124 (63) | 75 (38) | 123 (62) | 72 (36) | 126 (64) | 80 (40) | 118 (60) | Â | |
Residence | Urban | 106 (45) | 131 (55) | 78 (33) | 159 (67) | 84 (35) | 153 (65) | 38 (46) | 45 (54) | 38 (46) | 45 (54) | Â |
Rural | 35 (42) | 48 (58) | 36 (43) | 47 (57) | 44 (53) | 39 (47) | 92 (39) | 145 (61) | 87 (37) | 150 (63) | Â | |
Educational status | No | 24 (49) | 25 (51) | 16(33) | 33 (67) | 21 (43) | 28 (57) | 18 (37) | 31 (63) | 16 (33) | 33 (67) | Â |
Primary | 38 (43) | 50 (57) | 32(36) | 56 (64) | 35 (40) | 53 (60) | 40 (45) | 48 (55) | 38 (43) | 50 (57) | Â | |
Secondary | 57 (44) | 74 (56) | 49(37) | 82 (63) | 50 (38) | 81 (62) | 48 (37) | 83(63) | 52 (40) | 79 (60) | Â | |
Tertiary | 22 (42) | 30 (58) | 17(33) | 35 (67) | 22 (42) | 30 (58) | 24 (46) | 28 (54) | 19 (36) | 33 (64) | Â | |
WHO clinical stage | Stage I | 19 (46) | 22 (54) | 12(29) | 29 (71) | 13 (32) | 28 (68) | 14 (34) | 27 (66) | 13 (32) | 28 (68) | Â |
Stage II | 23 (41) | 33 (59) | 22(39) | 34 (61) | 20 (36) | 36 (64) | 24 (43) | 32 (57) | 25 (45) | 31 (55) | Â | |
Stage III/IV | 99 (44) | 124 (56) | 80(36) | 143(64) | 95 (43) | 128(57) | 92 (41) | 131 (59) | 87 (39) | 136 (61) | Â | |
Baseline CD 4 count | < 200 cell/μl | 30 (38) | 50 (62) | 25(31) | 55 (69) | 24 (30) | 56 70) | 30 (38) | 50 (62) | 21 (26) | 59 (74) |  |
> 200 cell/μl | 111(46) | 129 (54) | 89(37) | 151 (63) | 104 (43) | 136 (57) | 100 (41) | 140 (58) | 104 (43) | 136 (57) |  | |
BMI at baseline | Under weight | 47 (48) | 50 (52) | 37 (38) | 60 (62) | 39 (40) | 58 (60) | 43 (44) | 54 (56) | 44 (45) | 53 (55) | Â |
Normal | 70 (41) | 101 (59) | 61 (36) | 110 (64) | 68 (40) | 103 (60) | 70 (41) | 101 (59) | 56 (33) | 115 (67) | Â | |
Over weight | 24 (46) | 28 (54) | 16 (31) | 36 (69) | 21 (40) | 31 (60) | 17 (33) | 35 (67) | 25 (48) | 27 (52) | Â | |
Opportunistic infection | No | 120 (43) | 158 (57) | 03(37) | 175 (63) | 116 (63) | 162 (58) | 103 (39) | 171 (61) | 109 (39) | 169 (61) | Â |
Yes | 21 (50) | 21 (50) | 11 (26) | 31 (74) | 12 (29) | 30 (71) | 23 (55) | 19 (45) | 16 (38) | 26 (62) | Â | |
AZT-based HAART regimen | AZT + 3TC + NVP | 94 (44) | 118 (56) | 78 (37) | 134 (63) | 79 (37) | 133 (63) | 88 (42) | 124 (58) | 87 (41) | 125 (59) |  |
AZT + 3TC + EFV | 41 (43) | 54 (57) | 31 (33) | 64 (67) | 45 (47) | 50 (53) | 37 (39) | 58 (61) | 34 (36) | 61 (64) |  | |
AZT + 3TC + ATV/r | 6 (55) | 5 (45) | 5 (45) | 6 (55) | 3 (27) | 8 (73) | 4 (36) | 7 (64) | 4 (36) | 7 (64) |  | |
AZT + 3TC + NVP/r | 0 (0) | 2 (100) | 0 (0) | 2 (100) | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 0 (0) | 2 (100) |  | |